{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:11:26Z","timestamp":1749096686502,"version":"3.41.0"},"reference-count":49,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3538,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anxiety disorders are currently one of the most common health concerns in the United States. Overall, they are the single largest cost to the healthcare system. They are also underdiagnosed and undertreated. Selective serotonin reuptake inhibitors and benzodiazepines appear to be the most common pharmacologic treatment approaches. Unfortunately, not all patients respond to these treatments. Many augmentation strategies have been tried in the past with varying levels of success or safety. This article describes a safe and highly effective augmentation technique in patients suffering from some of the most serious and debilitating forms of anxiety disorders, namely obsessive-compulsive disorder and panic disorder.<\/jats:p>","DOI":"10.1017\/s1092852900010002","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T04:42:13Z","timestamp":1470112933000},"page":"176-179","source":"Crossref","is-referenced-by-count":12,"title":["Ziprasidone as an Augmenting Agent in the Treatment of Anxiety-Spectrum Disorders"],"prefix":"10.1017","volume":"10","author":[{"given":"Daniel L.","family":"Crane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"doi-asserted-by":"publisher","key":"S1092852900010002_ref010","DOI":"10.1176\/appi.ajp.157.4.659-a"},{"key":"S1092852900010002_ref012","first-page":"587","article-title":"Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases","volume":"24","author":"Sun","year":"2001","journal-title":"Chang Gung Med J"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref038","DOI":"10.1016\/S0024-3205(00)00911-5"},{"key":"S1092852900010002_ref026","first-page":"97","article-title":"Management of treatment-refractory panic disorder","volume":"35","author":"Matthew","year":"2001","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900010002_ref014","first-page":"303","article-title":"Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder","volume":"57","author":"Saxena","year":"1996","journal-title":"J Clin Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref016","DOI":"10.4088\/JCP.v61n0709"},{"key":"S1092852900010002_ref029","first-page":"55","article-title":"Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS","volume":"26","author":"Khullar","year":"2001","journal-title":"J Psychiatry Neurosci"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref022","DOI":"10.1001\/archpsyc.57.8.794"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref025","DOI":"10.1097\/00004714-200302000-00015"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref049","DOI":"10.1176\/appi.ajp.161.5.818"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref042","DOI":"10.1097\/00004714-200204000-00016"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref004","DOI":"10.1002\/(SICI)1520-6394(1999)9:3<107::AID-DA2>3.0.CO;2-T"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref045","DOI":"10.1023\/A:1020464017021"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref023","DOI":"10.1017\/S1461145703003730"},{"key":"S1092852900010002_ref008","first-page":"20","article-title":"Refractory obsessive-compulsive disorder: state-of-the-art treatment","volume":"63","author":"Hollander","year":"2002","journal-title":"J Clin Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref037","DOI":"10.1016\/S0014-2999(99)00005-9"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref044","DOI":"10.1034\/j.1600-0447.2000.101006416.x"},{"key":"S1092852900010002_ref048","first-page":"6","article-title":"The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice","volume":"64","author":"Stahl","year":"2003","journal-title":"J Clin Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref031","DOI":"10.1097\/00004714-200210000-00004"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref036","DOI":"10.1016\/S0014-2999(01)01188-8"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref043","DOI":"10.2165\/00023210-200216010-00003"},{"key":"S1092852900010002_ref028","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1176\/ajp.156.5.799","article-title":"Olanzapine-induced obsessive-compulsive disorder","volume":"156","author":"Mottard","year":"1999","journal-title":"Am J Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref033","DOI":"10.1177\/070674370304801012"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref047","DOI":"10.1176\/appi.ajp.161.8.1334"},{"key":"S1092852900010002_ref002","first-page":"11","article-title":"Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs","volume":"57","author":"Katon","year":"1996","journal-title":"J Clin Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref015","DOI":"10.4088\/JCP.v60n0804"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref017","DOI":"10.1097\/00004850-200015050-00007"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref013","DOI":"10.1097\/00004850-200201000-00006"},{"key":"S1092852900010002_ref006","first-page":"205","volume-title":"Panic Disorder and its Treatment","author":"Roy-Byrne","year":"1998"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref018","DOI":"10.1177\/070674370104600408"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref027","DOI":"10.1176\/jnp.16.1.113"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref020","DOI":"10.1016\/S0278-5846(03)00050-2"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref046","DOI":"10.1097\/01.jcp.0000095347.32154.08"},{"key":"S1092852900010002_ref007","first-page":"69","article-title":"Therapeutic strategies for the patient with treatment-resistant anxiety","volume":"54","author":"Coplan","year":"1993","journal-title":"J Clin Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref041","DOI":"10.1097\/00004850-200209000-00001"},{"key":"S1092852900010002_ref030","first-page":"55","article-title":"Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS","volume":"26","author":"Alevizos","year":"2001","journal-title":"J Psychiatry Neurosci"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref021","DOI":"10.1097\/00004850-200205000-00004"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref019","DOI":"10.4088\/JCP.v63n0807"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref011","DOI":"10.1192\/bjp.177.6.567-a"},{"key":"S1092852900010002_ref001","first-page":"4","article-title":"The epidemiology of anxiety disorders: prevalence and societal costs","volume":"63","author":"Lepine","year":"2002","journal-title":"J Clin Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref040","DOI":"10.1016\/S0006-3223(00)00850-7"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref003","DOI":"10.1176\/appi.ajp.157.5.669"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref032","DOI":"10.1089\/104454603322126386"},{"key":"S1092852900010002_ref034","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1176\/ajp.155.6.855","article-title":"Worsening of obsessive-compulsive symptoms following treatment with olanzapine","volume":"155","author":"Morrison","year":"1998","journal-title":"Am J Psychiatry"},{"key":"S1092852900010002_ref009","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1176\/ajp.156.11.1834-a","article-title":"Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder","volume":"156","author":"Marazziti","year":"1999","journal-title":"Am J Psychiatry"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref024","DOI":"10.1176\/jnp.13.1.113"},{"unstructured":"Ability [package insert]. Rockville, Md: Otsuka America Pharmaceutical, Inc; 2004.","key":"S1092852900010002_ref039"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref005","DOI":"10.1001\/archpsyc.1989.01810010038006"},{"doi-asserted-by":"publisher","key":"S1092852900010002_ref035","DOI":"10.1016\/S0924-977X(00)00096-1"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900010002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:57:11Z","timestamp":1749034631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900010002\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S1092852900010002"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900010002","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"type":"print","value":"1092-8529"},{"type":"electronic","value":"2165-6509"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}